{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Obeticholic+acid&page=2", "query": { "intervention": "Obeticholic acid", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Obeticholic+acid&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Obeticholic+acid&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T17:40:31.218Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05239468", "title": "Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Bezafibrate 100 mg", "type": "DRUG" }, { "name": "Bezafibrate 200 mg", "type": "DRUG" }, { "name": "Obeticholic Acid 5 mg", "type": "DRUG" }, { "name": "Obeticholic Acid placebo", "type": "DRUG" }, { "name": "Bezafibrate Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-03-21", "completion_date": "2025-09-01", "has_results": true, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239468" }, { "nct_id": "NCT01904539", "title": "Hepatic Impairment Trial of Obeticholic Acid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "obeticholic acid 10 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2013-06", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2013-10-24", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 2, "location_summary": "Miami, Florida • Orlando, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01904539" }, { "nct_id": "NCT05292872", "title": "Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [], "intervention_types": [], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4577, "start_date": "2015-06-01", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05292872" }, { "nct_id": "NCT02177136", "title": "Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Sclerosing Cholangitis (PSC)" ], "interventions": [ { "name": "Obeticholic Acid (OCA)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 77, "start_date": "2015-02-09", "completion_date": "2018-03-22", "has_results": true, "last_update_posted_date": "2021-07-08", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02177136" }, { "nct_id": "NCT04939051", "title": "Obeticholic Acid for Prevention in Barrett's Esophagus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Barrett Esophagus", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Esophageal Biopsy", "type": "PROCEDURE" }, { "name": "Esophagogastroduodenoscopy", "type": "PROCEDURE" }, { "name": "Liver Ultrasonographic Elastography", "type": "PROCEDURE" }, { "name": "Obeticholic Acid", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-01-03", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 8, "location_summary": "Kansas City, Kansas • Ann Arbor, Michigan • St Louis, Missouri + 2 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04939051" }, { "nct_id": "NCT02654236", "title": "Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alcohol Consumption" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "10 mg Obeticholic Acid (OCA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Suthat Liangpunsakul", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2016-04", "completion_date": "2019-09", "has_results": true, "last_update_posted_date": "2023-04-25", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02654236" }, { "nct_id": "NCT02633956", "title": "Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "Obeticholic Acid", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 84, "start_date": "2015-12-04", "completion_date": "2018-03-12", "has_results": true, "last_update_posted_date": "2018-06-04", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 22, "location_summary": "Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Rialto", "state": "California" }, { "city": "Inverness", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02633956" }, { "nct_id": "NCT05223036", "title": "Testing Obeticholic Acid for Familial Adenomatous Polyposis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Attenuated Familial Adenomatous Polyposis", "Colorectal Carcinoma", "Duodenal Carcinoma", "Familial Adenomatous Polyposis" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Gastrointestinal Endoscopy", "type": "PROCEDURE" }, { "name": "Obeticholic Acid", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-01-19", "completion_date": "2026-04-17", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05223036" }, { "nct_id": "NCT01933503", "title": "Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "OCA 5 mg", "type": "DRUG" }, { "name": "OCA 10 mg", "type": "DRUG" }, { "name": "OCA 25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2013-10", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2013-12-05", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933503" }, { "nct_id": "NCT01265498", "title": "The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Fatty Liver Disease (NAFLD)", "Nonalcoholic Steatohepatitis (NASH)" ], "interventions": [ { "name": "obeticholic acid", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 283, "start_date": "2011-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2018-04-06", "last_synced_at": "2026-09-30T17:40:31.218Z", "location_count": 9, "location_summary": "San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265498" } ] }